- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Biotech Stocks At 52-Week Highs - Amylyx Pharmaceuticals +63% With Phase 3 Data, Vogenx +25%, Orchestra BioMed +19%, AtriCure, Charles River Laboratories | 662 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 18, 2026, primarily driven by positive quarterly reports.Amylyx Pharmaceuticals Inc. (AMLX)Amylyx Pharmaceuticals... ► Artikel lesen | |
| 10.08. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates | 178 | GlobeNewswire (Europe) | The BACKBEAT global pivotal trial ("BACKBEAT Trial"), conducted in collaboration with Medtronic, is on track to reach its target of 284 evaluable randomized patients by end of Q3 2026, with primary... ► Artikel lesen | |
| 10.08. | Orchestra BioMed Holdings, Inc. Q2 Sales Decline | 1 | RTTNews | ||
| 29.06. | Aufnahme in Russell Indizes treibt Aktie von Orchestra BioMed an | 2 | Investing.com Deutsch | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 29.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Joins Russell 3000 and Russell 2000 Indexes | 243 | GlobeNewswire (Europe) | NEW HOPE, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to... ► Artikel lesen | |
| 23.06. | Orchestra BioMed Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 02.06. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.05. | Orchestra BioMed targets completed BACKBEAT enrollment by end of Q3 2026 | 8 | MassDevice | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates | 546 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking... ► Artikel lesen | |
| 12.05. | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.05. | Orchestra BioMed targets Q3 2026 enrollment for hypertension trial | 3 | Investing.com | ||
| 12.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 | 300 | GlobeNewswire (Europe) | Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, "Medtronic"), the Company's... ► Artikel lesen | |
| 06.05. | Orchestra Biomed picks up $35M from Medtronic, Ligand | 15 | MassDevice | ||
| 06.05. | Medtronic investiert 20 Millionen US-Dollar in Orchestra BioMed | 43 | Investing.com Deutsch | ||
| 06.05. | Orchestra BioMed receives $15 million from Ligand financing deal | 1 | Investing.com | ||
| 06.05. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement | 511 | GlobeNewswire (Europe) | $15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty... ► Artikel lesen | |
| 30.04. | Orchestra BioMed wins FDA breakthrough nod for pacemaker in hypertension | - | MassDevice | ||
| 23.04. | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 | 1 | GlobeNewswire (USA) | ||
| 26.03. | Jefferies senkt Kursziel für Orchestra BioMed wegen Finanzierungskosten | 2 | Investing.com Deutsch | ||
| 26.03. | Jefferies cuts Orchestra BioMed stock price target on financing costs | 1 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 78,23 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,330 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,760 | 0,00 % | H.C. Wainwright raises Relay Therapeutics price target to $29 | ||
| VERA THERAPEUTICS | 33,680 | -0,12 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,510 | 0,00 % | H.C. Wainwright hebt Kursziel für Tango Therapeutics auf 68 US-Dollar an | ||
| ARCUTIS BIOTHERAPEUTICS | 24,780 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 38,150 | 0,00 % | Kaum zu fassen: Die unglaubliche Biotech-Story von Amylyx Pharmaceuticals | Der Biotech-Sektor ist immer wieder für faustdicke Überraschungen gut - sowohl negativ als auch positiv. Bei Amylyx Pharmaceuticals gibt es am Dienstag keine zwei Meinungen: Die Aktie des Biotech-Unternehmens... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 61,15 | 0,00 % | William Blair startet Coverage für Enliven Therapeutics mit "Outperform" | ||
| APOGEE THERAPEUTICS | 134,81 | +0,01 % | AbbVie schließt Anleiheemission über 8,0 Mrd. US-Dollar zur Finanzierung der Übernahme von Apogee Therapeutics ab | ||
| JANUX THERAPEUTICS | 18,600 | 0,00 % | JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know | ||
| PRAXIS PRECISION MEDICINES | 368,25 | +0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,250 | 0,00 % | Recursion, Novavax and Crispr Stocks Trending in Pre-Market-Here's Why | ||
| INHIBRX BIOSCIENCES | 104,94 | 0,00 % | Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target | ||
| SUMMIT THERAPEUTICS | 12,730 | 0,00 % | Summit Therapeutics: Aktie legt nach Hochstufung durch Bernstein zu | ||
| NURIX THERAPEUTICS | 26,270 | 0,00 % | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen |
Das Unternehmen ORCHESTRA BIOMED HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,440 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.